Cargando…

Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care

Introduction: Dalbavancin is an antibiotic administered by intravenous infusion weekly or bi-weekly and is currently FDA-approved only for treatment of skin and soft-tissue infections. It has shown promise, but is not considered the standard of care, for bacteremia and infective endocarditis (IE), w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ajaka, Leama, Heil, Emily, Schmalzle, Sarah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602462/ https://www.ncbi.nlm.nih.gov/pubmed/33076275 http://dx.doi.org/10.3390/antibiotics9100700

Ejemplares similares

Dalbavancin for Staphylococcus aureus Bacteremia: Are We There Yet?
por: Mahatanan, Rattanaporn, et al.
Publicado: (2023)

1829. Dalbavancin versus standard of care as directed therapy for Staphylococcus aureus bacteremia in patients unable to receive OPAT
por: Frazier, J, et al.
Publicado: (2022)

A Dalbavancin for Successful Treatment of Infective Endocarditis Caused by Enterococcus faecalis
por: Teigell-Muñoz, Francisco Javier, et al.
Publicado: (2023)

Use of dalbavancin in infective endocarditis: a case series
por: Guleri, Achyut, et al.
Publicado: (2021)

2171. Clinical Characteristics and Outcomes of Immunocompromised Patients with Enterococcal Pneumonia
por: Ajaka, Leama, et al.
Publicado: (2022)

Streptococcus pyogenes Infective Endocarditis—Association With Injection Drug Use: Case Series and Review of the Literature
por: Rebechi, Melanie T, et al.
Publicado: (2021)

971. Pharmacokinetic Estimation Analysis of Multi-Dose Regimens of Dalbavancin for Treatment of Osteomyelitis or Bacteremia
por: Volk, Cecilia, et al.
Publicado: (2023)

Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections
por: Molina, Kyle C, et al.
Publicado: (2022)

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

Effectiveness of Dalbavancin Compared With Standard of Care for the Treatment of Osteomyelitis: A Real-world Analysis
por: Cain, Alexander R, et al.
Publicado: (2021)

108. Efficacy of Dalbavancin Compared to Standard of Care for the Treatment of Osteomyelitis: A Retrospective Study
por: Cain, Alexander, et al.
Publicado: (2021)

Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: A retrospective matched cohort study
por: Almangour, Thamer A., et al.
Publicado: (2020)

687. Use of Dalbavancin in Gram-positive Infective Endocarditis: Review of Current Literature
por: Fazili, Tasaduq, et al.
Publicado: (2021)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

2255. The Use of Dalbavancin for Staphylococcus aureus Bacteremia in Persons Who Inject Drugs (PWID)
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

279. Dalbavancin for Bloodstream Infections and Endocarditis: Real-World Outcomes From the DRIVE Registry
por: Gonzalez, Pedro, et al.
Publicado: (2020)

2362. Emergency Department Resource Utilization After Implementation of a Dalbavancin Pathway for Skin and Soft-Tissue Infections
por: Heil, Emily, et al.
Publicado: (2018)

Evolution of Antibiotic Tolerance During Oxacillin, Daptomycin and Dalbavancin Therapy Results in Breakthrough Staphylococcus aureus Bacteremias
por: Berti, Andrew, et al.
Publicado: (2017)

DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2019)

Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial
por: Turner, Nicholas A., et al.
Publicado: (2022)

Erysipelothrix Bacteremia; is Endocarditis a Rule?
por: Challa, Haripriya Reddy, et al.
Publicado: (2022)

Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections
por: Bork, Jacqueline T., et al.
Publicado: (2019)

Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis
por: Kussmann, Manuel, et al.
Publicado: (2018)

Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin
por: Loupa, Chariclia V., et al.
Publicado: (2020)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Dalbavancin: novel candidate for COVID-19 treatment
por: Hoffmann, Markus, et al.
Publicado: (2021)

Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals
por: Bai, Francesca, et al.
Publicado: (2023)

Dalbavancin: a novel antimicrobial
por: Chen, A Y, et al.
Publicado: (2007)

Recurrence of bacteremia and infective endocarditis according to bacterial species of index endocarditis episode
por: Østergaard, Lauge, et al.
Publicado: (2023)

Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source—a series of four cases
por: Hitzenbichler, Florian, et al.
Publicado: (2020)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
por: Tuan, Jessica J., et al.
Publicado: (2022)

Whole-genome sequencing of carbapenem-resistant Enterobacterales isolates and evaluation of hospital-acquired infections
por: Ajaka, Leama, et al.
Publicado: (2023)

217. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program (2018-202)
por: Sader, Helio S, et al.
Publicado: (2021)

New evidence on the use of fosfomycin for bacteremia and infectious endocarditis
por: Veganzones, Javier, et al.
Publicado: (2019)

Risk of endocarditis among patients with coagulase-negative Staphylococcus bacteremia
por: Ramos-Martínez, Antonio, et al.
Publicado: (2023)

Dalbavancin Use for the Treatment of Methicillin-resistant Staphylococcus aureus Pneumonia
por: Barber, Katie E., et al.
Publicado: (2017)

Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review
por: Buzón-Martín, Luis, et al.
Publicado: (2021)

Publisher Correction: Dalbavancin: novel candidate for COVID-19 treatment
por: Hoffmann, Markus, et al.
Publicado: (2022)

Staphylococcus hominis cellulitis and bacteremia associated with surgical clips
por: Uddin, O., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7l40uup7lgm6jlkm81qdvb7774